Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 9541 participants.
Also called NCT05202509
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 9,541 participants
- Registry
-
NCT05202509
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Bulgaria, Canada, China, Croatia, Czechia, Denmark, Finland, Georgia, Germany, Hungary, Israel, Italy, Japan, Jordan, Latvia, Netherlands, Poland, Slovakia, South Africa, Spain, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05202509. Randomized; quadruple masking; primary purpose treatment. Start 2022-02-07 (actual); primary completion 2026-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
- Acronym
- PREVAIL
- Condition
- Atherosclerotic Cardiovascular Disease
- Intervention (Drug)
- Obicetrapib
- Intervention (Drug)
- Placebo
- Lead sponsor
- NewAmsterdam Pharma
- Collaborator
- Monash University
Record details
- Record id
cardio:ct-nct05202509- Content hash
85a56884c4c567262b859d97cb8696722593b861434e1228ef5acab7260a518d